GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Exagen Inc (FRA:E08A) » Definitions » Outpatient Services Income Percentage of Revenue %

Exagen (FRA:E08A) Outpatient Services Income Percentage of Revenue % : 0.00% (As of . 20)


View and export this data going back to 2019. Start your Free Trial

What is Exagen Outpatient Services Income Percentage of Revenue %?

Outpatient Services Income Percentage of Revenue % gives the percentage of revenue dedicated to outpatient services income.

The historical rank and industry rank for Exagen's Outpatient Services Income Percentage of Revenue % or its related term are showing as below:


Exagen Outpatient Services Income Percentage of Revenue % Historical Data

The historical data trend for Exagen's Outpatient Services Income Percentage of Revenue % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Exagen Outpatient Services Income Percentage of Revenue % Chart



Exagen  (FRA:E08A) Outpatient Services Income Percentage of Revenue % Explanation

Outpatient services are medical procedures or tests that can be done in a medical center without an overnight stay.


Exagen Outpatient Services Income Percentage of Revenue % Related Terms

Thank you for viewing the detailed overview of Exagen's Outpatient Services Income Percentage of Revenue % provided by GuruFocus.com. Please click on the following links to see related term pages.


Exagen (FRA:E08A) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Exagen Inc (FRA:E08A) » Definitions » Outpatient Services Income Percentage of Revenue %
Traded in Other Exchanges
Address
1261 Liberty Way, Vista, CA, USA, 92081
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.

Exagen (FRA:E08A) Headlines

No Headlines